Quectel and MediaTek Unveil Next Generation 5G-A and Wi-Fi 8 Intelligent CPE Reference Design at MWC 2026
3.3.2026 14:38:00 CET | Business Wire | Press Release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of a new intelligent CPE reference design based on the MediaTek T930 platform, integrating 5G-Advanced and Wi-Fi 8 technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303124613/en/
Quectel and MediaTek unveil next generation 5G-A and Wi-Fi 8 intelligent CPE reference design at MWC 2026
The solution combines the high-performance 5G-A connectivity, intelligent reliability and advanced capabilities of the MediaTek T930 platform with Quectel’s deep expertise in the global Fixed Wireless Access (FWA) market. Moving beyond a simple focus on high speed, it delivers a fully integrated, all-in-one solution featuring exceptional performance, ultra-high stability, and intelligent network management.
Designed for both residential and enterprise users, the solution enables transformative improvements in broadband access, mobile office connectivity, enterprise networking, and industrial IoT applications. Powered by Quectel’s RG660MK series modules, the solution adopts MediaTek’s advanced 4nm T930 5G platform, integrating a 3GPP Release 18-compliant 5G-A modem, quad-core CPU and dedicated network processing unit, with chip-level deep collaboration with Wi-Fi 8 technology, bringing users a disruptive intelligent connectivity experience.
"As a global enabler in the IoT industry, we are committed to translating state-of-the-art connectivity technologies into customer value. The FWA market is evolving from basic connectivity to differentiated, intelligent and scenario-based experiences,” commented Doron Zhang, COO, Quectel Wireless Solutions. “Our new intelligent solution developed with MediaTek responds precisely to this trend, aiming to become the core network hub for future smart homes and digital enterprises. Going forward, Quectel will continue to deepen innovation in 5G and AIoT, collaborate with partners to empower all industries with more advanced and intelligent connectivity, and jointly prosper the global digital economy ecosystem."
Evan Su, General Manager of Wireless Communications at MediaTek, said "We are delighted to partner with Quectel to launch this landmark next-generation intelligent solution. It demonstrates our joint innovation strengths in 5G-A, Wi-Fi 8 and other cutting-edge technologies, and marks a key step toward a smarter FWA ecosystem. We look forward to deepening cooperation with Quectel in technical research, product development and ecosystem building, delivering stronger and superior next-gen connectivity solutions for global operators and end users, and jointly shaping the future of wireless broadband."
Powered by 8Rx and 3Tx 5L technologies, the reference design expands 5G coverage and cell-edge efficiency by 40%, delivering stable, high-speed connectivity even in weak-signal areas and dense multi-user environments. With MediaTek’s L4S feature cutting latency to just 1/20 of traditional systems, it ensures ultra-responsive performance for cloud gaming, real-time control, and HD video conferencing. Wi-Fi 8 technologies, including Coordinated Spatial Reuse, Coordinated Beamforming, and dynamic spectrum management, further reduce interference, boost transmission efficiency by over 25%, and increase device throughput by up to 80%, keeping hundreds of devices running smoothly. A built-in NPU adds edge intelligence capabilities such as autonomous optimization, local voice interaction, and dynamic end-edge-cloud coordination, transforming the network from a passive pipe into an intelligent, proactive platform.
With sub-millisecond latency and ultra-reliable performance, it powers 8K UHD streaming, immersive VR/AR, and seamless whole-home smart device connectivity. For enterprises, it enables fast, flexible deployment of high-speed wireless broadband, ideal for branch offices, temporary sites, and areas without wired infrastructure. It also delivers cost-effective broadband access for underserved regions, while meeting the stringent low-latency and reliability demands of industrial IoT, telemedicine, smart education, and precision agriculture.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global end-to-end IoT solutions provider backed by outstanding support and services.
With a worldwide team of over 5,800 professionals, we lead the way in delivering end-to-end IoT solutions, spanning cellular, GNSS, satellite, Wi-Fi and Bluetooth modules, high-performance antennas, value-added services and full turnkey offerings including ODM services and system integration.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com or LinkedIn
View source version on businesswire.com: https://www.businesswire.com/news/home/20260303124613/en/
Contacts
Media contact: media@quectel.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press Release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press Release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press Release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press Release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press Release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom